132 related articles for article (PubMed ID: 7912011)
1. [Progress in the treatment of hairy cell leukemia. Subcutaneous administration of 2-chloro-deoxy-adenosine for 7 days].
Heldal D; Tjønnfjord GE; Evensen SA; Juliusson G
Tidsskr Nor Laegeforen; 1994 Mar; 114(7):800-3. PubMed ID: 7912011
[TBL] [Abstract][Full Text] [Related]
2. [Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine].
Nielsen OJ; Hippe E; Priø TK; Juliusson G
Ugeskr Laeger; 1994 Apr; 156(16):2407-9. PubMed ID: 7912015
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA).
Robak T; Krykowski E; Błasińska-Morawiec M; Urbańska-Ryś H
Arch Immunol Ther Exp (Warsz); 1994; 42(1):25-9. PubMed ID: 7503629
[TBL] [Abstract][Full Text] [Related]
6. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
7. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hairy cell leukemia patients with 2-chloro-2'-deoxyadenosine (2-CdA).
Komarnicki M; Kaźmierczak M; Hansz J
Arch Immunol Ther Exp (Warsz); 1994; 42(1):31-2. PubMed ID: 7503630
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hairy cell leukemia with cladribine].
Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
13. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.
Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M
Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908
[TBL] [Abstract][Full Text] [Related]
14. [Hairy cell leukemia treated with cladribine].
Ghanima W; Heldal D; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment with cladribine for hypoplastic hairy cell leukemia after long-term neutropenia].
Sakai R; Yamazaki E; Sakamoto H; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2005 Nov; 46(11):1187-90. PubMed ID: 16440801
[TBL] [Abstract][Full Text] [Related]
16. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.
Juliusson G; Heldal D; Hippe E; Hedenus M; Malm C; Wallman K; Stolt CM; Evensen SA; Albertioni F; Tjønnfjord G
J Clin Oncol; 1995 Apr; 13(4):989-95. PubMed ID: 7707128
[TBL] [Abstract][Full Text] [Related]
18. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
[TBL] [Abstract][Full Text] [Related]
19. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia.
Yang MH; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):54-8. PubMed ID: 11310372
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]